Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Current therapies for adults with newly diagnosed B-ALL have complete remission (CR) rates of 60%–90%. In relapsed or refractory (R/R) B-ALL cases, chemotherapy achieves CR rates of 31%–44% during first salvage therapy and 18%–25% during second salvage therapy. For patients who achieve a second CR after re-induction chemoimmunotherapy, allogeneic hematopoietic cell transplantation (HCT) remains the standard of care. The absence of measurable residual disease (MRD) in the marrow after intensive multi-agent cytotoxic chemotherapy is the most predictive factor for better clinical outcomes in B-ALL. Persistent MRD at the time of allogeneic HCT is associated with higher relapse rates. Historically, treatment options for R/R B-ALL were limited to conventional cytotoxic chemotherapies, resulting in CR rates of 30%–40% for the first salvage and 10%–20% for the second salvage. This has driven the development of novel therapies to improve outcomes in adult R/R ALL. Antibody-targeted therapies and chimeric antigen receptor (CAR) T-cell therapies have emerged as significant advancements in managing R/R ALL. Monoclonal antibodies targeting cell surface antigens like CD20, CD19, and CD22 work through complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, or direct phagocytosis. With nearly all precursor and mature B cells expressing CD19 and over 90% of precursor and all mature B cells expressing CD22, blinatumomab (Blincyto, Amgen) and inotuzumab ozogamicin (Besponsa, Pfizer) are highly effective antibody-targeted therapies.

Thelansis’s “Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033